NCT02106091 - Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

August 31, 2018

Study Completion Date

September 30, 2018

Conditions

Relapsed B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin Lymphoma

Interventions

DRUG

AFM11

Accelerated-titration dose-escalation with 1 patient per dose-level, followed by standard dose-escalation (3 + 3 design), Treatment duration: 4 weeks.

Trial Locations (9)

11636

Charles Hospital Prague, Prague

24105

University Hospital, Kiel

31501

SP ZOZ University Hospital Krakow, Krakow

55131

University Medical Center of the Johannes Gutenberg University Mainz, Mainz

66421

University Hospital of the Saarland, Homburg/Saar

89081

University Hospital, Ulm

97080

University Hospital, Würzburg

02111

Tufts Medical Center, Boston

02106

MTZ Clinical Research, Warsaw